Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of Respirgard II and Isoneb Nebulizers for Lung Delivery
NCT02277808Phase 1Unknown
- Start
- Dec 2013
- Primary completion
- Oct 2014
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial (2 arms). Primary endpoint: Amikacine urinary dosage at 24 hours. Status: unknown.
Beyond the preview
Go deeper on NCT02277808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02277808.